Gyre Therapeutics, Inc. filings document a commercial-stage biopharmaceutical issuer with U.S. and China operations, revenue from Gyre Pharmaceuticals, and a pipeline centered on anti-fibrotic therapies and targeted protein degradation assets. Form 8-K reports cover operating results, business updates, CDE/NMPA regulatory disclosures for F351, and clinical-program updates for Hydronidone and pirfenidone.
Proxy and material-event filings describe governance matters, shareholder voting items, material agreements, capital-structure disclosures and the completed Cullgen acquisition, including preferred-stock and common-stock conversion mechanics. The record also includes Regulation FD disclosures addressing commercial products, research spending and pipeline development.
Gyre Therapeutics, Inc. filed Amendment No. 1 to a current report to add audited and interim financial statements for its newly acquired subsidiary Cullgen Inc. and unaudited pro forma condensed combined financials following their all-stock merger valuing Cullgen at approximately $300 million.
Cullgen generated $15,373 (in thousands) of collaboration revenue in 2025, primarily from an Astellas agreement, and recorded a net loss of $10,805 (in thousands), driven by research and development expenses of $19,330 (in thousands) and general and administrative expenses of $10,246 (in thousands). Year-end cash and cash equivalents were $12,122 (in thousands) with short-term investments of $28,085 (in thousands).
For the three months ended March 31, 2026, Cullgen reported collaboration revenue of $1,911 (in thousands) versus $8,513 (in thousands) a year earlier and a net loss of $8,719 (in thousands), leading to an accumulated deficit of $144,834 (in thousands). Management states that existing cash, cash equivalents and short-term investments are expected to fund operations for at least 12 months, while the company continues to anticipate ongoing operating losses.
Gyre Therapeutics, Inc., a commercial-stage biopharmaceutical company, filed a pre-effective amendment to its Form S-3 to register up to 31,302,863 shares of common stock for resale by existing stockholders, increasing the original 30,221,531-share registration by 1,081,332 shares.
The Resale Shares comprise 11,735,356 merger shares issued in the Cullgen acquisition, 18,486,175 shares issuable upon conversion of 3,697,235 Series B Preferred Shares, 540,666 PIPE shares, and 540,666 shares issuable upon conversion of Series X Preferred Stock via a warrant. Gyre will not receive proceeds from stockholder resales, and will receive cash only if the warrant is exercised for cash at $4,915.00 per share.
Common stock outstanding was 111,488,849 shares as of May 31, 2026, a baseline figure, not the amount being registered. The company highlights significant PRC-related legal and regulatory risks, HFCAA-driven audit and potential delisting risks, and notes that entities affiliated with GNI Japan would retain a majority stake even if all their registered shares are sold.
Gyre Therapeutics director Carmichael Gordon received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $5.95 per share, expire on June 10, 2036, and will vest in 12 equal monthly installments through June 10, 2027, contingent on continued service.
GYRE THERAPEUTICS, INC. director David M. Epstein received a grant of stock options to acquire 40,000 shares of common stock. The options have an exercise price of $5.95 per share and expire on June 10, 2036.
The award was made as a compensation-related grant, with no cash purchase by the insider at grant. According to the terms, the options will vest in 12 equal monthly installments through June 10, 2027, so long as Epstein continues to provide service to the company through each vesting date.
GYRE THERAPEUTICS, INC. director Dan Weng received a stock option grant covering 40,000 shares of common stock. The option has an exercise price of $5.95 per share and expires on June 10, 2036.
The award vests in 12 equal monthly installments through June 10, 2027, conditioned on continued service. After this grant, Weng holds stock options for 40,000 underlying shares directly, reflecting routine equity-based compensation rather than an open-market transaction.
GYRE THERAPEUTICS, INC. director Renate Parry received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $5.95 per share and expire on June 10, 2036. According to the disclosure, the award vests in 12 equal monthly installments through June 10, 2027, contingent on Parry’s continued service to the company. This is a compensation-related acquisition, with no open‑market buying or selling reported in this filing.
GYRE THERAPEUTICS, INC. director Zhang Ping received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $5.95 per share, expire on June 10, 2036, and vest in 12 equal monthly installments through June 10, 2027 as long as service continues.
Gyre Therapeutics director Rodney L. Nussbaum received a new stock option grant for 40,000 shares of common stock. The option, with an exercise price of $5.95 per share, gives him the right to buy Gyre Therapeutics stock at that price until June 10, 2036.
The award was reported as a compensation-related grant, not an open-market purchase or sale. The option will vest in 12 equal monthly installments through June 10, 2027, subject to his continued service with the company. After this grant, he holds options for 40,000 underlying shares directly.
Gyre Therapeutics, Inc. is registering 30,221,531 shares of Common Stock for resale by selling stockholders. The registration covers up to 11,735,356 Common Shares and 18,486,175 Conversion Series B Shares issuable upon conversion of 3,697,235 Series B Preferred Shares, with conversion subject to stockholder approval required by Nasdaq (the "Conversion Approval").
The company states it will receive no proceeds from sales of the Resale Shares; net proceeds will be received by the selling stockholders. The filing arises from the May 4, 2026 merger with Cullgen and implements registration rights under a Registration Rights Agreement. Shares outstanding were 111,488,849 as of May 31, 2026.
GYRE THERAPEUTICS, INC. Chief Operating Officer Weiguo Ye reported a series of option exercises paired with open-market sales of common stock. On June 9, 10, and 18, he exercised stock options at $0.75 per share to acquire a total of 11,000 shares of common stock, then sold 11,000 shares in open-market transactions at prices reported around $6.15–$6.35 per share. A footnote states some sales were reported as a weighted average with individual trades between $6.20 and $6.30 per share. After these transactions, Ye directly holds 700,000 shares of Gyre Therapeutics common stock.